The Transformative Health Instrument (THI) call invites micro, small, and medium enterprises (SMEs) to submit applications for funding to support the development of scalable health technologies in Biotech, Medtech, Digital Health & AI, Biomarker/Diagnostics or a combination of these. Applicants should address unmet needs in Europe with novel and commercially viable approaches, scientific excellence, and strong internal capabilities.
This call aims to strengthen integration between the research and business sides of the knowledge triangle by accelerating healthcare innovations borne out of research to support commercial and business growth of small and micro enterprises in European markets. All funded projects under this Call are expected to generate the following outcomes and long-term impact.
Projects may request between € 300 000 and € 500 000 in EIT Health funding.
EIT Health will fund a maximum of 50% of the project’s total costs. The company must secure the remaining 50% co-funding from other sources.
The expected duration of participation is 12 months (January 2027-December 2027).
The call is intended to support private companies, specifically Micro, Small and Medium-sized enterprises (SMEs), with at least 4 full-time equivalent employees. Eligible companies must have closed a minimum total equity investment of €2.000.000 within the previous 36-months, with at least one new investor contributing.
In accordance with the Horizon Europe Work Programme, to be eligible for funding, the applicant must be established in one of the eligible countries, i.e.:
Companies should be focused on innovations within the healthcare sector, specifically Biotech, Medtech, Digital Health & AI, Biomarker/Diagnostics or a combination of these.
Funded projects must be at the Innovation Maturity Levels (IML) listed below, depending on their industry focus: